GeneFx Lung diagnostic data

A validation study analyzing 181 frozen, resected stage I/II NSCLC tumor specimens showed that Med BioGene's GeneFx Lung classified the samples into high- and low-risk prognostic groups with significantly different OS (p=0.012). In a subgroup analysis, the test predicted survival in 127 stage I patients (p=0.018) as well as in a smaller subgroup of 48 stage IA patients (p=0.014). Furthermore, the test was prognostic for both adenocarcinoma (p=0.058) and squamous cell carcinoma (SCC) cases (p=0.045). Data were published in the Journal of Thoracic Oncology. ...